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ORIGINAL ARTICLE
Differential diagnosis of gallstones by using hypericin as a 
fluorescent optical imaging agent
Basic Study
Marlein Miranda Cona, Ye-Wei Liu, Antoine Hubert, Ting Yin, Yuan-Bo Feng, Peter de Witte, Etienne Waelkens, 
Yan-Sheng Jiang, Jian Zhang, Stefaan Mulier, Qian Xia, Gang Huang, Raymond Oyen, Yi-Cheng Ni
differential fluorescent detection of human gallstones.
METHODS: Cholesterol, mixed and pigment stones 
from cholecystectomy patients were incubated with 
hypericin or solvent. After 72 h, the stones were 
analysed for fluorescence (365 nm) and treated with 
2-propanol/dimethyl sulfoxide for high performance 
liquid chromatography (HPLC) analysis. Rats with 
virtual gallbladder containing human cholesterol, 
mixed or pigment gallstones (VGHG) received 5 mg/kg 
hypericin or solvent and VGHG rats with cholesterol 
stones were given different hypericin doses (5-15 mg/
kg). Twelve hours later, the stones were analysed at 
365 nm. Biliary excretion and metabolites of hypericin 
were assessed in common bile duct (CBD) cannulated 
rats for 9 h using fluorospectrometry, HPLC and matrix-
assisted laser desorption/ionization-time-of-flight mass 
spectrometry (MALDI-TOF MS).
RESULTS: Homogeneous high fluorescence was 
seen on cholesterol stones either pre-incubated with 
hypericin or extracted from VGHG rats receiving 
hypericin. Mixed stones showed a dotted fluorescent 
pattern, whereas pigment and solvent-treated ones 
lacked fluorescence. HPLC showed 7.68, 6.65 and 0.08 
× 10-3 M of cholesterol in extracts from cholesterol, 
mixed, and pigment gallstones, respectively. Hypericin 
accounted for 2.0, 0.5 and 0.2 × 10-6 M in that order. 
On cholesterol stones from VGHG rats receiving 
different hypericin doses, a positive correlation was 
observed between dose and fluorescence. In the bile 
from CBD-cannulated rats, fluorescence represented 
20% of the injected dose with two peaks in 9 h. HPLC 
analysis revealed that hypericin conjugates reached 
60% of the peak area. By MALDI-TOF MS, hypericin-
glucuronide was detected. 
CONCLUSION: This study proves the potential use of 
hypericin for differential fluorescent detection of human 
gallstones regarding their chemical composition.
Key words: Differential detection; Fluorescence; Human 
gallstones; Hypericin; Rat model of cholelithiasis
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Cholelithiasis refers to cholesterol, mixed and 
pigment gallstones in the gallbladder. Although the 
current diagnostic methods may detect their presence 
in the biliary system, none of them may offer an in 
situ  differential diagnosis of gallstones regarding 
their chemical composition. Hypericin is a fluorophore 
plant pigment tending to bind membrane lipids and is 
excreted via  bile. Because cholesterol is likely the target 
that hypericin binds, hypericin could become a potential 
optical imaging agent for differential fluorescent 
detection of gallstones. Such imaging procedures would 
allow identifying the origin, composition and formation 
of gallstones in patients and permit adopting strategies 
to minimize cholelithiasis recurrence.
Miranda Cona M, Liu YW, Hubert A, Yin T, Feng YB, de Witte P, 
Waelkens E, Jiang YS, Zhang J, Mulier S, Xia Q, Huang G, Oyen 
R, Ni YC. Differential diagnosis of gallstones by using hypericin 
as a fluorescent optical imaging agent. World J Gastroenterol 
2016; 22(29): 6690-6705  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v22/i29/6690.htm  DOI: http://dx.doi.
org/10.3748/wjg.v22.i29.6690
INTRODUCTION
Hypericin is a pigment originated from the Hypericum 
perforatum (St. John’s Wort) plant and has been 
used as an herbal medicine due to its biological 
properties[1-3]. Recently, hypericin has been identified 
as a potent necrosis avid agent with numerous medical 
applications[4,5]. Several mechanisms underlying its 
necrosis avidity have been proposed. Exposed sites 
of degraded life molecules present in necrotic cell 
remnants[6], albumins[7] and low-density lipoproteins 
(LDL)[8] have been suggested as the targets of 
hypericin. Its affinity for lipid components such as 
cholesterol, phosphatidylethanolamine (PE) and 
phosphatidylserine (PS) from cell membrane bilayer 
has been reported[9,10].
Cholelithiasis is a common abdominal disorder 
worldwide[11-13] and refers to the presence of gallstones 
in the gallbladder. Cholelithiasis can cause acute 
gallbladder inflammation and infection by intestinal 
bacteria with symptoms of pain, jaundice and 
fever[14,15]. Gallstones are bile concretions that can 
differ in size, pathogenesis and composition, and are 
caused by the precipitation of cholesterol, bilirubin and 
cholates (or bile salts)[11]. According to the published 
classification system based on their compositions[16], 
gallstones can be divided into cholesterol stones 
(having ≥ 70% of cholesterol); mixed stones 
comprising palmitate phosphate, calcium carbonate, 
bilirubin and other bile compounds (30%-69% of 
cholesterol); and pigment stones consisting of bilirubin 
and calcium salts (< 30% of cholesterol)[17,18]. 
Among diagnostic methods for gallbladder diseases 
including cholelithiasis are interventional approaches 
such as duodenal drainage, endoscopic ultrasonography 
and endoscopic retrograde cholangiopancreato-
graphy (ERCP) as well as noninvasive sonography, 
cholescintigraphy, oral cholecystogram, intravenous 
cholangiogram (IVC), computed tomography (CT), 
magnetic resonance cholangiopancreatography (MRCP) 
and blood tests[18-20]. Although these techniques may 
help to find the presence of gallstones, thickening of the 
gallbladder wall, pericholecystic fluid and occurrence 
of ductal obstruction, none of them can offer a differen-
tial diagnosis of gallstones regarding their chemical 
composition[18]. However, if available, such imaging 
procedures would be of added value for identifying 
the origin of gallstone formation in a given patient and 
consequently allow adopting preventive strategies for 
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minimizing cholelithiasis recurrence. 
It was during the mechanism studies of hypericin 
affinity that this new imaging procedure for differential 
diagnosis of gallstones has been explored. Hypericin 
is known to bind to membrane lipids[9,21], be strongly 
fluorescent, and be mainly excreted into the bile[22]. 
We therefore hypothesized that: (1) cholesterol is 
most likely the target lipid that hypericin binds; and 
(2) hypericin could be a potential optical imaging 
agent for differential fluorescent detection of gallstones 
in clinic. Indeed, hypericin is a polycyclic aromatic 
naphthodianthrone with excellent fluorophore pro-
perties including high brightness and photostability. 
When it absorbs external energy from an elec-
tromagnetic radiation in the range from 300 to 400 
nm, it fluoresces in the orange-red region between 
600 and 650 nm[23,24], making it a good candidate for 
optical imaging. 
To test these hypotheses, we evaluated the inte-
raction of hypericin with gallstones derived from pati-
ents subjected to cholecystectomy. In vitro studies 
were done by testing the affinity of hypericin with 
cholesterol, mixed and pigment gallstones. To quantify 
the amount of cholesterol and hypericin in the stones, 
two chromatographic methods were developed and 
validated. For the suitability of hypericin in differential 
detection of gallstones, in vivo experiments were 
conducted in an animal model of cholelithiasis[25]. To 
better understand in which form hypericin is present 
in the bile for interacting with the gallstones, the 
hepatobiliary pathway of hypericin and its metabolites 
in the bile were studied in rats with common bile duct 
(CBD) drainage.
MATERIALS AND METHODS
The experimental procedures included in this paper are 
shown in Figure 1.
Chemicals 
Cholesterol, 3β-hydroxy-5-cholestene (purity ≥ 
99%) was purchased from Sigma-Aldrich (United 
States). Hypericin (1,3,4,6,8,13-hexahydroxy-10,11-
dimethylphenanthro [1,10,9,8-opqra]perylene-7,14-
dione, purity ≥ 98%) was obtained from Planta Natural 
Products (Austria; http://www.planta.at/hyper/hyper.
htm). The solvents were Ph. Eur reagent grade and 
acquired from commercial sources. For solubilization, 
hypericin was dissolved in dimethyl sulfoxide (DMSO)/
polyethylene glycol-400 (PEG-400)/propylene glycol 
(PG)/water (H2O) (25%:25%:25%:25%, v/v/v/v).
Biological materials
The experiments were performed using cholesterol, 
mixed and pigment stones from the gallbladder of 
cholecystectomy patients (n = 3) at the Department 
of Abdominal Surgery, Leopold Park Clinic, CHIREC 
Cancer Institute, Brussels, Belgium.
In vitro studies
Preparation of standard solutions: Calibration 
curves of hypericin and cholesterol were built. From a 
6692 August 7, 2016|Volume 22|Issue 29|WJG|www.wjgnet.com
Figure 1  Flowchart of the experimental procedures. CBD: Common bile duct; CHOL: Cholesterol; DMSO: Dimethyl sulfoxide; HYP: Hypericin; IPA: 2-propanol; 
PEG: Polyethylene glycol; PG: Propylene glycol; RP-HPLC: Reverse phase-high performance liquid chromatography; MALDI-TOF MS: Matrix-assisted laser 
desorption-ionization time-of-flight mass spectrometry; MIX: Mixed; PIG: Pigment; RT: Room temperature. 
In vitro  studies
CHOL, MIX, PIG 
stones
CHOL stones
HYP 2 × 10-3 M
DMSO/PEG-400/PG/H2O
(25/25/25/25%, v/v/v/v)
HYP 
2 × 10-5 - 2 × 10-3 M
DMSO/PEG-400/PG/H2O
72 h, RT, darkness
Macroscopy
Fluorescence
 assay (365 nm)
Extraction 
(CHIL, HYP)
DMSO/IPA
RP-HPLC 
method validation (CHOL, HYP)
In vivo  studies
Cholelithiasis rats (n  = 15)
CHOL stones
5, 10, 15 mg/kg HYP
DMSO/PEG-400/PG/H2O
(25/25/25/25%, v/v/v/v)
Cholelithiasis rats (n  = 30)
CHOL, MIX, PIG stones 
5 mg/kg HYP in
DMSO/PEG-400/PG/H2O
Or only solvent
HYP
 DMSO/PEG-400/H2O
(25/60/15%, v/v/v)
12 h
Macroscopy
Fluorescence 
assay (365 nm) 
RP-HPLC
Determination (CHOL, HYP)
Bile collection
0-9 h
Fluorospectrometry
Fluorescence-HPLC
MALDI-TOF MS
CBD-cannulated 
rats (n  = 6)
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Analysis of cholesterol, mixed and pigment 
stones pre-incubated with hypericin: Cholesterol, 
mixed and pigment stones were incubated with 2 × 
10-3 M hypericin or only with the solvent. Hypericin 
non-treated gallstones were set as controls. After 72 
h of incubation, the stones were rinsed with distilled 
water and dried using paper towels. They were pho-
tographed (Canon Digital IXUS 860 IS, Japan) in a 
CN-15 darkroom cabinet (Vilber Lourmat Deutschland 
GmbH, Eberhardzell, Germany) under white light and 
at an excitation wavelength of 365 nm for assessment 
of physical and fluorescent properties, respectively. 
For cholesterol and hypericin quantification, the 
stones were separately crushed with an agate mortar. 
Ten mg of each type of powdered stone was treated 
with 3.0 mL of DMSO/IPA (50%:50%, v/v) under 
stirring for 1 h, at room temperature under dim-
light. The samples were centrifuged for 5 min at 5000 
rpm at 4 ℃. Aliquots from the supernatants were 
analyzed by RP-HPLC, as described in section 2.3.2. 
The percentage of cholesterol in each type of stone 
was estimated. The concentrations of cholesterol and 
hypericin in the DMSO/IPA extracts were determined 
from the regression equation of their corresponding 
calibration curves. 
Interaction of cholesterol stones with hypericin 
at different concentrations: Cholesterol stones 
were treated with hypericin at 2 × 10-5, 2 × 10-4 and 2 
× 10-3 M or only with the solvent for 72 h. After rinsing 
and drying, the stones were photographed under white 
light and at 365 nm in a CN-15 darkroom cabinet. 
In vivo interaction of cholesterol stones and hypericin 
Animals: Fifty-one Wistar rats (male, 8-10 wk, 
300-350 g) were used. The animals were purchased 
from Charles River Breeding Laboratories, Inc. (St. 
Aubain les Elbeuf, France). One week before the 
experiments, they were housed under environmentally 
controlled conditions (temperature 23 ± 2 °C, relative 
humidity 60% ± 10%, 12:12 h light-dark cycle). 
Standard rat chow (Ssniff Spezialdiäten GmbH, Soest, 
Germany) and water were available ad libitum. The 
experiments were approved by the local animal 
ethics committee and were performed according to 
the European Ethics Committee guidelines (decree 
86/609/EEC).
Fluorescent detection of human stones in a 
rat model of cholelithiasis receiving a given 
hypericin dose: Model rats with virtual gallbladder 
having implanted either cholesterol, mixed or 
pigment stones (VGHG) were prepared, as previously 
described[25]. Animals were imaged by MRI using a 
3.0 T Siemens Trio whole-body scanner (Siemens, 
Erlangen Germany) to monitor the dilatation of the 
CBD and to detect the location of the gallstone(s) in 
the virtual gallbladder. 
stock solution of 5.2 × 10-2 M cholesterol in DMSO/2-
propanol (IPA) (50%:50%, v/v), sequential dilutions 
were performed to obtain standard solutions including 
2.6, 5.2, 7.8, 10.3 and 12.9 × 10-3 M. For hypericin, a 
stock solution at 4.0 × 10-5 M in DMSO/IPA (50%:50%, 
v/v) was prepared and diluted at the concentrations of 
0.6, 1.3, 2.5, 5 and 10 × 10-6 M. A blank of DMSO/IPA 
(50%:50%, v/v) was included for both compounds. 
The solutions were assessed by reverse phase (RP)-
high performance liquid chromatography (HPLC). 
Chromatographic conditions: The chromatographic 
analysis was done with a Hitachi Elite LaChrom 
HPLC system (Auckland, New Zealand) equipped 
with an L-2130 pump and an XTerra C18 reverse-
phase analytical column (5.0 µm 4.6 × 150 mm; 
Waters, United States). The sample injection was 
made through a Rheodyne Model 7725 injector. The 
column was eluted with a 30 min-gradient of 10% to 
90% acetonitrile in 5.0 mM ammonium acetate pH 
7.0 at 1.0 mL/min. For cholesterol, an L-2450 diode 
array detector at 204 nm was used. With hypericin, 
an L-2480 fluorescent detector was set with excitation 
and emission wavelengths of 470 and 600 nm, 
respectively. Data acquisition and processing were 
performed with EZChrom Elite version 3.1.6 developed 
by Scientific Software Inc. The peak areas (PAs) and 
retention times (RTs) were recorded. 
Validation of the chromatographic methods: 
Two RP-HPLC methods for cholesterol and hypericin 
were validated, as described in the ICH harmonized 
tripartite guidelines[26,27]. For assessment of column 
efficiency, peak symmetry and precision, four re-
plicates of the blank and the five standard solutions 
of cholesterol and hypericin were used. Column 
efficiency was reported as the number of theoretical 
plates (N > 2000)[28]. Peak symmetry was represented 
as peak asymmetry (As) and tailing factor (TF < 
2.0)[28]. Precision was reported as the percentages of 
the relative standard deviation (%RSD < 1.0) of the 
PAs and RTs[28]. Accuracy was evaluated by recovery 
measurements of 2.6 × 10-3 M cholesterol and 5.0 × 
10-6 M hypericin at 80%, 100% and 120% levels in 
triplicate. The recovery percentages and %RSD values 
were determined[29]. 
Calibration curve preparation: To build the standard 
curves of cholesterol and hypericin, the RP-HPLC-
peak areas on Y-axis and the concentration of the 
blank and the five standard solutions on X-axis were 
plotted and fit to a straight line, using linear regression 
analysis[27]. The slope, Y-intercept, regression equation 
and regression coefficient (R2) of the calibration curves 
were determined. The limits of detection (LOD) and the 
limits of quantification (LOQ) were calculated based on 
the slope of the corresponding calibration curves and 
the standard deviations of their responses[28,29].
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According to the gallstones classification by 
composition, VGHG rats with cholesterol, mixed or 
pigment stones were allocated in three groups (n = 5 
each). Under intraperitoneal (IP) Nembutal anesthesia 
(30 mg/kg), the rats were intravenously (IV) given 1 
× 10-3 M hypericin at 5.0 mg/kg via the penile vein. 
The other three groups of VGHG rats (n = 5) with 
cholesterol, mixed or pigment stones receiving only 
solvent were used as controls. Twelve hours later, the 
animals were sacrificed with an overdose Nembutal 
of 100 mg/kg. The stones were extracted from the 
animals, rinsed and photographed under white light 
and fluorescence (365 nm) in a CN-15 darkroom 
cabinet. 
Fluorescent detection of cholesterol stones in 
a rat model of cholelithiasis receiving different 
hypericin doses: Three groups of anesthetized rats 
(n = 5 each) with virtual gallbladder having embed-
ded cholesterol gallstones were IV given 1 × 10-3 M 
hypericin at 5, 10 or 15 mg/kg. After 12 h, the animals 
were killed with anaesthetic overdose and the internal 
organs were exposed. The animal and the extracted 
cholesterol stones were photographed in a CN-15 
darkroom cabinet under white light and at 365 nm, 
with hypericin non-treated stones set as controls.
Analysis of biliary metabolites of hypericin 
To investigate in which form hypericin is present in the 
bile for interacting with the stones, CBD-ligated rats 
were prepared by ligation of the CBD in six normal 
rats with a non-absorbable silk suture. The resulting 
enlarged CBD were cannulated using polyethylene (PE) 
tubing (0.58 mm ID and 0.96 mm OD, Natume Co., 
Tokyo, Japan) for bile collection. 
The CBD-ligated rats then received IV 1 × 10-3 M 
hypericin at 10 mg/kg, and biliary juice was hourly 
collected from 0 to 9 h. Bile samples were transferred 
to a 96-well black polystyrene plate (Greiner Bio-
One; Kremsmünster, Austria) and measured on 
a plate reader (FLUOstar OPTIMA, BMG Labtech, 
Offenburg, Germany) with excitation and emission 
filters of 485 and 590 nm wavelengths, respectively. 
The fluorescence concentrations versus time curves 
were built and the area under the curve from 0 up 
to 9 h (AUC0-9 h) was determined using the linear/
logarithmic trapezoidal rule. 
Bile samples were also analyzed by RP-HPLC using 
UV and fluorescence detection. Solutions of 1.3 × 
10-5 M hypericin either in DMSO/PEG-400/PG/H2O 
(25%:25%:25%:25%, v/v/v/v) or bile were also 
analyzed.
The fluorescent HPLC peaks from bile analysis 
were collected and evaluated by matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry 
(MALDI-TOF MS) as described previously[30]. After 
digestion and extraction of the tryptic peptides, the 
samples were dried down, desalted onto Millipore 
ZipTip C18 (Bedford, MA, United States) and analyzed 
by MS on a MALDI-TOF/TOF 4800 instrument (Applied 
Biosystems, Foster City, United States)[30]. Data 
interpretation was performed with the GPS Explorer 
software (Version 3.5), and database searching was 
done using the Mascot program (Version 2.2) (www.
matrixscience.com). 
Statistical analysis
The numerical results are expressed as mean ± stan-
dard deviation (SD). Statistical analyses were per-
formed using GraphPad Prism (version 4.0; GraphPad, 
San Diego, United States) by one-way analysis of 
variance (ANOVA). P values < 0.05 were considered 
statistically significant.
RESULTS
General aspects 
Solutions: Cholesterol solutions in DMSO/IPA (50%:50%, 
v/v) at different concentrations were transparent with-
out any turbidity. Different concentrations of hypericin 
either in DMSO/IPA (50%:50%, v/v) or DMSO/
PEG-400/PG/H2O (25%:25%:25%:25%, v/v/v/v) 
showed a light pink to bright red color without any 
discernible aggregates. 
Stone morphology: Each cholecystectomy patient 
had several stones with similar size and morphology. 
However, marked variations in sizes and shapes of 
the stones were observed from different human 
subjects. Cholesterol stones were yellow polyhedrons 
having a smooth surface. Mixed stones appeared to 
have a yellow color, with large brown patches on their 
irregular surface. Pigment stones looked dark brown. 
Gallstones sized between 0.1 and 1.0 cm with various 
shapes ranging from round to faceted. 
Animal models: The rat model of surgically induced 
virtual gallbladder with human cholesterol, mixed and 
pigment stones was successfully established in all 
animals[25], as confirmed by MRI (Figure 2). 
No animals died due to the anesthetics and surgical 
procedures. For CBD-ligated rats, all the animals 
survived the anesthesia, surgery and cannulation 
process. None of them was excluded from the study 
because of procedural complications. The process 
proved to be safe and took around 20 min for each 
animal.
In vitro studies 
Validation of the chromatographic methods 
for cholesterol and hypericin quantification in 
gallstones: For cholesterol quantification, a blank 
and five standard solutions were prepared from 
2.6 to 12.9 × 10-3 M in DMSO/IPA (50%:50 %, 
v/v). Chromatograms were obtained by RP-HPLC 
and diode array detection at 204 nm (Figure 3A). 
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Table 1 presents the PAs and the RTs for the studied 
concentrations of cholesterol. Good column efficiency 
with a high number of theoretical plates (N) around 
7700 was observed. The As and TF were 1.02 and 1.0, 
respectively (Table 2). The chromatographic method 
showed reliability, accuracy and precision. For replicate 
injections of five different concentrations of cholesterol, 
high precision was seen with %RSD values of the PAs 
below 1.7%. Low variability (%RSD < 1.3%) in RTs 
was observed (Table 3). The method exhibited a good 
accuracy having %RSD below 1.6% and recovery 
values of 99.8%, 100.3%, and 99.6% at 80%, 100% 
and 120% concentration levels, respectively (Table 4). 
Figure 3B depicts the calibration curves cor-
responding to the mean chromatogram peak areas 
of cholesterol at different concentrations. The chroma-
Figure 2  Transverse T2 weighted MR scanning images in a rat model of cholestasis-induced virtual gallbladder (yellow arrow) before (A) and after (B) 
implantation of a human gallstone (red arrow). 
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Figure 3  Validation of the chromatographic methods for cholesterol and hypericin quantification in gallstones. A1-B2: Validation data of the analysis by 
reverse phase-high performance liquid chromatography on hypericin pre-incubated human gallstones with UV (204 nm) and fluorescence detection (excitation/
emission wavelengths: 470/600 nm). A typical UV chromatogram of 5.2 × 10-3 M cholesterol with a retention time (RT) of 19 ± 0.22 min (A1) and the HPLC-generated 
calibration curve (A2) based on four replicate measurements of five working solutions of cholesterol are presented. A representative fluorescence chromatogram of 
1.3 × 10-6 M hypericin with an RT of 9.68 ± 0.06 min (B1) along with corresponding HPLC-generated calibration curve of hypericin (B2) is shown. FLU: Fluorescence 
units; mAu: Milli-absorbance units.
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tographic conditions used to build the calibration curve 
allowed an efficient identification of this compound. 
The slope, Y-intercept and regression equation of the 
curve are presented in Table 5. Good linearity was 
observed with correlation coefficients (R2) above 0.998. 
The LOD and LOQ were 0.58 × 10-3 M and 1.76 × 10-3 
M, respectively (Table 5). 
For hypericin, standard solutions with five different 
concentrations from 0.6 to 10 × 10-6 M and a blank 
were prepared in DMSO/IPA (50%:50%, v/v). Unlike 
cholesterol, RP-HPLC chromatograms for hypericin 
were obtained using fluorescence detection (Figure 3C). 
The PAs and their RTs for the studied concentrations 
are shown in Table 1. The chromatographic method 
appeared to be feasible, precise and accurate (Table 
2). A high number of theoretical plates (N = 5500) 
were determined, indicating good column efficiency. 
The As and TF were found to be around 0.75 and 0.61, 
respectively. For all replicate concentrations, the %RSD 
values of the PAs and RTs were less than 1.6% (Table 3). 
The accuracy of the method was excellent with %RSD 
lower than 1.5% and recovery values of 108.8%, 
101.7%, and 103.6% at 80%, 100% and 120% 
concentration levels, respectively (Table 4).
By using the mean PAs at different concentrations 
of hypericin, calibration curves were plotted and are 
presented in Figure 3D. The slope, Y-intercept and 
regression equation are indicated in Table 5. The HPLC 
conditions used to construct the standard curves 
permitted a good identification of hypericin in the 
studied range of concentrations. The plot showed a 
good fit for a linear model with R2 above 0.997. The 
LOD and LOQ were 0.64 × 10-6 M and 1.90 × 10-6 M, 
respectively (Table 5).
Interaction of different types of gallstones with 
hypericin: No solid depositions of solubilized stones 
fragments were macroscopically observed either in 
the solvent or at the bottom of the vials. At 365 nm, 
cholesterol gallstones showed a homogeneous red 
fluorescence on their surfaces. Mixed stones exhibited 
similar fluorescent intensity as that observed in 
cholesterol ones. However, the fluorescence signal 
had a heterogeneous distribution resembling a dotted 
pattern. In contrast, no fluorescence was noticed on 
the pigment stones and on the ones treated only with 
Table 1  Calibration data of the chromatographic methods
Cholesterol Hypericin
Conc. PA ± SD RT ± SD (min) Conc. PA ± SD RT ± SD (min)
(×10-3 M) (n  = 4) (×10-6 M) (n  = 4)
2.6 32715275 ± 532288 19.60 ± 0.19   0.6   961398 ± 14312 9.85 ± 0.14
5.2 64995700 ± 622439 19.83 ± 0.26   1.3 3120453 ± 33528 9.63 ± 0.03
7.8   91376450 ± 1113357 19.79 ± 0.14   2.5 5782945 ± 90738 9.41 ± 0.13
10.3 124007250 ± 2116420  19.97± 0.11   5.0 10563681 ± 134692 9.75 ± 0.11
12.9 151245250 ± 2660042 20.03 ± 0.12 10.0 20814150 ± 226368 9.61 ± 0.07
Conc.: Concentration; PA: Peak area; RT: Retention time; SD: Standard deviation.
Table 2  System suitability 
System suitability parameters Cholesterol Hypericin
Theoretical plates (N) 7700 5500
Asymmetry factor (As)  1.02  0.75
Tailing factor (TF)  1.00  0.61
Table 3  Results of the intra-day precision studies
Cholesterol Hypericin
Conc. RSD-PA RSD-RT Conc. RSD-PA RSD-RT 
(×10-3 M) (×10-6 M)
2.6 1.6% 0.9%   0.6% 1.5% 1.4%
5.2 0.9% 1.3%   1.3% 1.1% 0.3%
7.8 1.2% 0.7%   2.5% 1.6% 1.4%
10.3 1.7% 0.5%   5.0% 1.3% 1.1%
12.9 1.7% 0.6% 10.0% 1.1% 0.7%
Conc.: Concentration; PA: Peak area; RSD: Relative standard deviation; 
RT: Retention time.
Table 4  Results of the recovery studies
Compound Labelled 
amount
Added 
amount
Found 
amount
Recovery RSD
Cholesterol 1.0 mg 0.80 mg 0.79 mg   99.8% 1.6%
1.00 mg 1.00 mg 100.0% 1.1%
1.20 mg 1.19 mg   99.6% 1.2%
Hypericin 0.0025 µg 0.0020 µg 0.0029 µg 108.8% 0.4%
0.0025 µg 0.0026 µg 101.7% 0.1%
0.0030 µg 0.0032 µg 103.6% 1.6%
RSD: Relative standard deviation; SD: Standard deviation.
Table 5  Linearity of the high performance liquid chroma-
tography methods for cholesterol and hypericin 
Compound LR Slope SD (LR) R2 LOD (M) LOQ (M)
Cholesterol y = 1 × 107 x 
+ 3 × 106
11712479 2055881 0.998 0.58 × 10-3 1.76 × 10-3
Hypericin y = 2 × 106x 
+ 2 × 105
  2066297   433480 0.998 0.69 × 10-6 2.1 × 10-6
LR: Linear regression; SD (LR): Standard deviation of regression line; R2: 
Coefficient of correlation; y: Peak area; x: Compound concentration; LOD: 
Limit of detection; LOQ: Limit of quantification.
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solvent (control) (Figure 4). 
Interaction of cholesterol stones with hypericin 
at different concentrations: At 365 nm, a stronger 
red fluorescence was observed on the surfaces of 
cholesterol stones pre-incubated with 2 × 10-3 M 
hypericin than that from those stones treated with 
lower concentrations (2 × 10-4 and 2 × 10-5 M). Among 
them, 2 × 10-5 M hypericin produced the lowest 
fluorescence signal on the stone surface (Figure 5). 
Quantification of hypericin and cholesterol in 
human stones: Figure 6 depicts chromatograms of 
DMSO/IPA (50%:50%, v/v) extracts from cholesterol, 
mixed and pigment stones obtained by RP-HPLC under 
diode array (204 nm) and fluorescence (excitation/
emission wavelengths: 470/600 nm) detections.
On UV-chromatograms of mixed and cholesterol 
stones, a single peak was observed at an RT of 19.99 
± 0.17 min, corresponding to the cholesterol contents 
in the gallstones. With pigment stones, however, two 
peaks were seen. The first large peak appeared at 
1.41 ± 0.02 min that seemed to correspond to other 
components which were present at higher amounts 
than cholesterol. The second small peak having an 
RT of 19.81 ± 0.11 min represented the cholesterol 
fraction in this type of stone. The concentrations of 
cholesterol in the DMSO/IPA extracts were 7.68, 
6.65 and 0.08 × 10-3 M representing percentages of 
81%-83%, 71%-75% and 1%-3% of the cholesterol, 
mixed and pigments stones, respectively (Table 6), 
which differ slightly from known classification[17,18]. 
By fluorescence detection for hypericin, a single 
peak with an RT of 9.68 ± 0.06 min was observed in 
all types of gallstones. Regarding its concentration, 
significant differences were found among cholesterol, 
mixed and pigment stones (P = 0.01). The highest 
contents were detected in cholesterol stones, whereas 
the lowest values were determined in the pigment 
ones. The concentrations of hypericin in the DMSO/IPA 
extracts were 2.0, 0.5 and 0.2 × 10-6 M for cholesterol, 
mixed and pigments stones, respectively (Table 6). 
In vivo studies 
Fluorescence detection of cholesterol, mixed and 
pigment stones in a rat model of cholelithiasis 
receiving hypericin: Cholelithiasis rats having 
cholesterol, mixed and pigment stones received IV 1 
× 10-3 M hypericin at 5 mg/kg. No unexpected side-
effects and good tolerability were observed. Cholesterol 
gallstones extracted from rats treated with hypericin 
showed high red fluorescence at 365 nm. Mixed 
Figure 4  Macroscopy and fluorescence observations of hypericin-treated human gallstones under white and UV (365 nm) lights. A yellow cholesterol stone 
(A1) showed homogeneous and red fluorescence on the surface (A2). A mixed stone with yellowish and brown patches (B1) revealed red fluorescence solely on the 
yellow cholesterol region (B2). A pigment stone appeared dark brown (C1) with almost no fluorescence (C2).
Macroscopy
Fluorescence
A1 B1 C1
A2 B2 C2
Table 6  Results of the analysis of cholesterol, mixed and 
pigment stones 
Type of 
stones
Cholesterol Hypericin P  
valueConc. (× 10-3 M) Percentage Conc. (× 10-6 M)
IPA/DMSO 
extracts
in stone IPA/DMSO 
extracts
Cholesterol 7.68 ± 0.25 83%-86% 2.01 ± 0.38
Mixed 6.65 ± 0.12 71%-75% 0.50 ± 0.19 0.011
Pigment 0.08 ± 0.02 1%-3% 0.23 ± 0.06
Conc.: Concentration; DMSO: Dimethyl sulfoxide; IPA: 2-propanol.
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stones exhibited similar fluorescent intensity but in a 
heterogeneous distribution pattern. In contrast, pigment 
stones or stones from the rats receiving only solvent 
showed no fluorescent signals (data not shown). 
Fluorescence detection of cholesterol stones in 
a rat model of cholelithiasis receiving different 
doses of hypericin: Cholelithiasis rats with cholesterol 
stones were IV given 1×10-3 M hypericin at doses 
of 5, 10 or 15 mg/kg, which were all safe and well-
tolerated. With 5 mg/kg, the stones exhibited relative 
lower fluorescence and, almost no signal was observed 
from the organs and tissues (Figure 7). After injecting 
hypericin at 10 mg/kg, stones exhibited high red 
fluorescence, with moderate signal intensity seen in the 
diaphragm and intestine (Figure 7). With 15 mg/kg, 
fluorescence in the midline surgical incision, mouth and 
testis skin was detected (data not shown) in addition 
to the high fluorescence intensity in gallstones as well 
as the diaphragm, intestine, stomach and pancreas. 
Overall, the results showed that the fluorescence 
intensity and the tissue distribution of hypericin 
were positively correlated with the injected dose. 
Interestingly, the liver was almost not fluorescent in all 
hypericin doses (Figure 7), likely due to non-fluorescent 
binding form of hypericin present in hepatocytes. 
In vivo studies on biliary excretion of hypericin in CBD-
cannulated rats
Bile collection in CBD-cannulated rats: The bile 
flow rate varied from 0.22 to 0.58 mL/h. It remained 
almost constant at 0.57 ± 0.01 ml/h over the first two 
hours, but dropped to 0.2 mL/h during the later 7 h. 
The total volume of bile collected was about 3.5 mL in 
Macroscopy
Fluorescence
Figure 5  Macroscopic digital imaging under white and UV (365 nm) lights of human cholesterol gallstones treated with different concentrations of 
hypericin (2 × 10-5 - 2 × 10-3 M) or only with solvent for 72 h. Solvent-treated stone (A1, A2) lacked fluorescence (A3, A4). Gallstones pre-incubated with hypericin 
solutions at 2 × 10-5 M (B1, B2), 2 × 10-4 M (C1, C2) and 2 × 10-3 M (D1, D2) exhibited fluorescence (B4, C4, D4), which seemed to increase with the hypericin 
concentration (B3, C3, D3). 
A1 B1 C1 D1
A2 B2 C2 D2
A3 B3 C3 D3
A4 B4 C4 D4
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the course of the nine hours. 
Fluorescence intensity over time in bile from 
CBD-cannulated rats after hypericin admini-
stration: Figure 8 gives the concentration curves of 
fluorescent species versus time in bile during 9 h after 
hypericin administration with two peaks observed. 
The first peak reached its highest value at 2 h. The 
second higher steep peak occurred at 5 h. From AUC 
calculation of concentration curves, the percentage of 
fluorescent species excreted into the bile within 9 h 
was 20% of the total administered dose of hypericin. 
Metabolite analysis 
Figure 9 shows fluorescence HPLC chromatograms for 
1.3 × 10-5 M hypericin dissolved either in solvent or 
bile as well as samples of bile from CBD-cannulated 
rats before hypericin injection at excitation/emission 
wavelengths of 470 and 600 nm. With only hypericin, 
a single narrow peak at an RT of 29.22 ± 0.09 min 
was seen (Figure 9A). Bile samples before receiving 
hypericin showed a single peak with a short RT of 1.67 
± 0.14 min that corresponded to the autofluorescent 
properties of the bile (Fig 9B). HPLC of hypericin in bile 
had two peaks of RT at 1.72 ± 0.22 min and 29.38 ± 
0.15 min, respectively (Figure 9C).
A fluorescent HPLC of bile at 2 h after hypericin 
injection is shown in Figure 10 with a total of 8 peaks. 
The first peak with an RT of 1.76 ± 0.11 min and 15% 
of area referred to the autofluorescent bile fraction. 
The 2nd and 3rd peaks overlapped at an RT of 4.27 ± 
0.09 min and 5.03 ± 0.25 min with 4.3% and 7.2% of 
Figure 6  HPLC chromatograms of dimethyl sulfoxide/2-propanol (50%:50%, v/v) extracts from hypericin pre-incubated gallstones with UV (204 nm) and 
fluorescence detection (excitation/emission wavelengths: 470/600 nm). Under UV, cholesterol and mixed stone extracts showed a main peak with a retention 
time (RT) of 19.99 ± 0.17 min corresponding to cholesterol. With fluorescence detection, a single peak of hypericin at 9.68 ± 0.06 min was observed. In pigment 
stone extracts, the UV showed a large peak at 1.41 ± 0.02 min representing other non-cholesterol components in this type of stone. The second small peak with an 
RT of 19.81 ± 0.11 min corresponding to cholesterol was also observed. Under fluorescence, pigment stone extracts showed a smaller peak of hypericin than that in 
cholesterol and mixed stones. FLU: Fluorescence units; mAu: Milli-absorbance units; HPLC: High performance liquid chromatography.
Cholesterol                                                                       Hypericin
Pi
gm
en
t 
st
on
es
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 M
ix
ed
 s
to
ne
s 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 C
ho
le
st
er
ol
 s
to
ne
s
600
400
200
0
-200
m
Au
0        4       8      12     16      20     24     28
                             t/min
60
50
40
30
20
10
0
FL
U
0        4       8      12      16     20     24     28
                             t/min
20
15
10
5
0
FL
U
0        4        8       12      16      20      24     28
                             t/min
600
400
200
0
-200
m
Au
0        4        8      12      16     20       24       28
                             t/min
8
6
4
2
0
FL
U
0         4        8       12       16      20      24      28
                             t/min
1600
1200
800
400
0
m
Au
0        4       8      12      16     20     24     28
                             t/min
Miranda Cona M et al . Differential diagnosis of gallstones with hypericin
6700 August 7, 2016|Volume 22|Issue 29|WJG|www.wjgnet.com
the total area, respectively. The 4th peak was detected 
at 10.42 ± 0.18 min with 26.6% of area. The 5th peak 
slightly overlapped with the 4th one came out at 12.95 
± 0.25 min with 37.6% of area. At longer RTs, the 
6th (22.50 ± 0.26 min) and 7th (23.16 ± 0.72 min) 
small peaks represented less than 4% of the biliary 
excretion, followed by the last peak with an RT of 
29.12 ± 0.03 min accounting for 15.8% of area that 
seemed to correspond to the intact hypericin (Figure 
10A and B). 
By MALDI-TOF MS, the collected fluorescent HPLC 
peaks were analyzed. Among them, however, only one 
peak (RT = 23.16 min) could be identified, which most 
likely represents the mono-glucuronide (m/z = 681. 
9594 Da) ion of hypericin (Figure 11). 
DISCUSSION
Gallstones are deposits in the gallbladder, which often 
instigate diseases including cholelithiasis and require 
treatments including surgery to remove the gallbladder 
and/or stone(s)[11-20]. These crystalline concretions 
differ in chemical compositions, indicating various 
mechanisms of formation and growth. Although 
some diagnostic techniques are clinically available for 
cholelithiasis, none of them offer a differential imaging 
diagnosis based on the chemical composition of the 
gallstones. The feasibility and availability of such a 
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15.0 mg/kg
A1 A2
B1 B2
C1 C2
A3
A4
B3 B4
C3
C4
Figure 7  Macroscopic digital imaging under white and UV (365 nm) lights in rats of cholelithiasis receiving intravenous 1 × 10-3 M hypericin at 5, 10, 15 
mg/kg and their corresponding extracted gallstones. Rats receiving hypericin at 5 mg/kg (A1) exhibited almost no fluorescence in organs (A2). The extracted 
gallstones (black arrow) showed faint fluorescent relative to control stones (A3, A4). With 10 mg/kg hypericin (B1), moderate fluorescence appeared in the diaphragm 
(B2). Higher red fluorescence in gallstones (black arrow) was observed as compared to control stone (B3, B4). Rats treated with 15 mg/kg hypericin (C1) revealed 
high fluorescence in visceral organs (C2). The stone (black arrow) displayed high fluorescence as compared to the control (C3, C4). 
2150
1900
1650
1400
1150
900
650
400
150
-100
0       1       2        3       4        5        6       7       8        9      10
                                           t/h
Fl
uo
re
sc
en
ce
 in
te
ns
ity
Figure 8  Nine-hour time-concentration curve of fluorescent species in 
bile from CBD-cannulated rats having received 1 × 10-3 M hypericin at 10 
mg/kg. Two peaks accounting for 20% of the administered dose were found at 
2 h and 5 h, suggesting enterohepatic circulation. 
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technique may help to better treat cholelithiasis and 
reduce its recurrence. 
In this study, we thought hypericin could be a 
potential fluorophore for the differential detection of 
gallstones by optical imaging. Literature shows that 
high amounts of hypericin selectively localized in 
cholesterol-rich microdomains than in less ordered 
lipid-rich areas[9]. Emission spectrum measurements 
indicated interactions between pi electrons of hypericin 
and cholesterol may lead to the formation of a packing 
arrangement between the common planar structures 
of the two molecules[9]. Based on these observations, 
we hypothesised that similar interaction could occur 
between hypericin and the cholesterol crystals (in 
gallstones), which are formed due to the inability to 
solubilize the lipid-bile salt micelles in cholesterol-
enriched bile. Moreover, the nearly 100% hypericin 
excretion in the bile could be a favourable feature 
for the exploration of this approach. Hypericin is 
highly lipophilic with a high octanol-water partition 
coefficient value (log P = 3.43)[31] and a molecular size 
of 504 g/mol. In its metabolic pathway, being taken 
up and excreted by hepatocytes, it passes via the 
bile from the liver through the CDB and gallbladder 
into the intestine[32]. This might facilitate the contact 
between hypericin and the stones located either in the 
gallbladder or biliary ducts. Furthermore, hypericin has 
a distinct fluorescent profile in the orange-red region 
(emission peak about 590 nm) which can offer high 
quality optical images. 
By testing in vitro, we proved the specificity and 
affinity of hypericin for the cholesterol present in the 
gallstones from cholecystectomy patients. Hypericin-
treated cholesterol gallstones showed high and 
homogeneous fluorescence covering their entire 
surfaces. In mixed stones with heterogeneous surface 
distribution of cholesterol, only spotted fluorescence 
was observed. Pigment stones having low cholesterol 
contents as well as hypericin-non treated stones 
exhibited no fluorescent properties. As it was expected, 
hypericin seemed to accumulate preferably in regions 
where high concentrations of cholesterol localized. 
In a second step to investigate the preferential 
hypericin accumulation in cholesterol-rich gallstones, 
Figure 9  HPLC chromatograms with fluorescence detection of 1.3 × 10-5 
M hypericin eluting at an RT of 29.22 min (A), bile alone with an RT of 
1.67 min (B) and 1.3 × 10-5 M hypericin in bile (C) with two above peaks 
(A, B) observed. FLU: Fluorescence units; HPLC: High performance liquid 
chromatography.
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Figure 10  A typical HPLC chromatogram with fluorescence detection of 
hypericin and its conjugated metabolites in bile from CBD-cannulated rats 
at 2 h after hypericin administration. Eight fluorescent peaks were observed. 
The peak at 1.76 min corresponded to the autofluorescence of the bile. The 
following six peaks with RT of 4.27, 5.03, 10.42, 12.95, 22.50 and 23.16 min 
appeared to represent hypericin in conjugated or metabolized forms. The last 
peak seemed to be unchanged hypericin eluting at 29.12 min (A). Spectrometry 
measurements of HPLC peaks confirmed the highest fluorescent signals from 
those with RT of 1.76, 10.42, 12.95 and 29.12 min (B). FLU: Fluorescence 
units; HPLC: High performance liquid chromatography.
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HPLC technique combined with the calibration curve 
method[33,34] was applied to determine cholesterol 
and hypericin contents in different types of human 
gallstones pre-incubated with hypericin. Both 
techniques, separately or in combination, have 
been applied for quantification of both compounds 
in different samples[35,36]. In this study, standards 
of either cholesterol or hypericin were assessed 
by HPLC and, then, the corresponding calibration 
curves were generated, allowing the quantification 
of both compounds in the gallstones by further 
curve-extrapolation. Although we used similar 
chromatographic conditions such as type and length of 
analytical column, mobile phase composition and flow 
rate, with different detectors included, the fluorescence 
detection of hypericin as the fluorophore was preferred 
due to its high sensitivity for identifying trace amounts 
of molecules in biological matrices[37]. With the non-
fluorescent cholesterol, instead, a diode array detector 
was set at a wavelength of 204 nm, as has been used 
in previous works[38]. For HPLC analysis, all the stones 
were treated with a solvent mixture consisting of 
DMSO/IPA (50%/50%, v/v) to simultaneously extract 
cholesterol and hypericin. The 2-propanol solvent has 
been used for cholesterol extraction from different 
biological fluids and tissues[39]. Regarding DMSO, it 
is the solvent of choice for dissolving water-insoluble 
hypericin[40]. After extrapolating the concentration 
of hypericin or cholesterol in the DMSO/IPA extracts 
from the stones to the corresponding calibration 
curves, cholesterol stones constantly showed the 
highest amounts of both compounds. Despite these 
results, it is important to note that the concentration 
of hypericin detected is thousand-fold smaller than 
the total cholesterol contents in the stones, likely due 
to binding of hypericin to the cholesterol-rich surfaces 
of the gallstone without going deeper into the internal 
cholesterol deposits of the stone. 
To make steps forward, we investigated the 
feasibility of using hypericin to detect different types 
of human gallstones in a rat model of cholelithiasis[25] 
by fluorescence optical imaging. Comparisons among 
groups of VGHG animals containing different types 
of gallstones supported our in vitro observations. 
Indeed, 12 h after giving hypericin to VGHG animals, 
cholesterol and mixed gallstones were fluorescent 
in contrast to the pigment stones which lacked 
fluorescent properties. Moreover, we tried to optimize 
in vivo the dose of hypericin needed to obtain a good 
ratio between the fluorescent signals from cholesterol 
stones and the background. Such a ratio could be 
hampered either by tissue autofluorescence or 
hypericin biodistribution/excretion. Indeed, the results 
showed dependence between the administered dose 
of hypericin and its accumulation in the stones and 
organs. This closely matched with our in vitro studies 
about the influence of hypericin concentration on the 
fluorescent intensity of cholesterol stones. It seems 
that a dose of 10 mg/kg offered the best outcome 
among the tested hypericin doses, with which highly 
fluorescent contrast on stones was detected relative 
to the low intestinal background. By injecting 15 mg/
kg hypericin, however, high fluorescence from both 
stones and tissues was observed, which interfered 
with the detection of gallstones. It may be due to the 
presence of hypericin remnants in the intestinal lumen 
Figure 11  MALDI TOF-TOF MS spectra of the HPLC-collected peak with an RT of 23.16 min which was isolated from bile of CBD-cannulated rats after 
administration of hypericin. A peak at m/z = 681.9594 Da could be identified (arrow), representing the mono-glucuronide ion of hypericin. CBD: Common bile duct.
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as its major excretion pathway[32,41]. With 5 mg/kg 
hypericin, no fluorescence from the background and 
faint fluorescent signal from the stones were observed. 
This could be due to that hypericin was almost cleared 
from the body and washed out from the surface of 
gallstones by the bile flow over 12 h. Despite these 
promising results, improvement is still needed. 
Because of the possible phototoxicity of hypericin[42], 
a dose of 10 mg/kg could harm the patients. Lower 
doses of hypericin along with shorter incubation time 
(< 12 h) for gallstone detection could be a solution to 
overcome this drawback. With further optimization, 
by using a safe dose, it could be possible to guarantee 
a good signal-to-noise ratio in fluorescence before a 
complete washout of hypericin from the stone surface.
An additional study was conducted on CBD-
cannulated rats for identifying hypericin species in 
the bile interacting with the stones. For this, the 
fluorescent properties of bile samples collected in 9 
h were assayed by fluorospectrometry, HPLC and 
MALDI TOF-TOF MS at the excitation and emission 
wavelengths for the fluorophore hypericin. A collection 
period of 9 h was chosen due to the decrease in the 
flow rate of drained biliary juice after long period of 
CBD cannulation, as was also observed in previous 
studies[43]. By HPLC, a profile of eight fluorescent 
species was observed along 9 h of bile collection. 
Hypericin was mainly excreted in conjugated 
fluorescent forms representing above 60% of the total 
peak area. This matched with previous results for 
iodinated-hypericin derivatives[43]. Importantly, such 
peaks could not be observed in a hypericin solution 
with the bile as a solvent. They only appear during 
the passage of hypericin through the liver. Because 
cholesterol is one of the major bile constituents and 
undergoes intestinal reabsorption[44], and since the 
affinity between cholesterol and hypericin has been 
reported[20,45], we initially thought both molecules 
might form complexes in their primary path through 
hepatocytes. However, the lipophilicity of both 
compounds does not explain the presence of hypericin 
conjugates observed during the RP-HPLC analysis, 
showing less lipophilic character due to their shorter 
RTs. An alternative reason is the possible hepatic 
glucuronidation of hypericin during bile excretion due 
to its relatively large molecular weight (504 g/mol) 
and chemical structure[32,41,46]. The glucuronic acid-
compounds are usually more soluble in water than 
non-glucuronic acid-containing compounds. This could 
explain the faster elution of the fluorescent hypericin 
metabolites compared to the intact hypericin from the 
hydrophobic HPLC column. Indeed, MALDI TOF-TOF 
MS showed a peak corresponding to a glucuronide 
hypericin specie, confirming our hypothesis. 
By fluorospectrometry, time-fluorescence con-
centration curves for hypericin revealed two fluorescent 
peaks in the bile. The first one is most likely related with 
the elimination of hypericin through the bile that came 
a few hours after administration. The second delayed 
peak may denote the enterohepatic circulation (EHC) 
of hypericin, in line with earlier reports on hypericin and 
its derivatives[32]. Consequently, hypericin is partially 
reabsorbed from intestinal lumen through the portal 
circulation. Indeed, previous studies on lipophilic 
compounds such as hypericin have shown the influence 
of EHC on their absorption, distribution, metabolism and 
excretion[32,47,48]. 
In conclusion, this study proves the feasibility 
of using the fluorophore hypericin for differential 
detection of human gallstones by their chemical com-
positions. This approach may assist in fluorescent 
detection and removal of cholesterol gallstones during 
open surgery and/or endoscopic cholecystectomy and 
cholangiotomy. Further research is deemed necessary 
before this approach could enter clinical applications. 
ACKNOWLEDGMENTS
The corresponding author is a Bayer Lecture Chair 
holder. 
COMMENTS
Background
Cholelithiasis refers to cholesterol, mixed and pigment gallstones in the biliary 
system especially the gallbladder, which is a common disorder of the digestive 
system. 
Research frontiers
Although current diagnostic methods may detect gallstones in the biliary 
system, none of them may offer an in situ differential diagnosis of gallstones 
regarding their chemical composition. 
Innovations and breakthroughs
Hypericin is a fluorophore plant pigment tending to bind lipids and is excreted 
via bile. Because hypericin presumably targets cholesterol, it could become 
a potential optical imaging probe for differential fluorescent detection of 
gallstones. This hypothesis was verified in vitro and in vivo in a rat model of 
human gallstones.
Applications 
Such imaging procedures would allow identifying the origin, composition and 
formation of gallstones in patients and permit adopting strategies to minimize 
cholelithiasis recurrence.
Peer-review
The manuscript is well written, the methodological part in particular. It deserves 
to be published. The authors consider the main benefit of this study to allow 
a differential detection of human gallstones regarding to their chemical 
composition. I am afraid this information has, today, little clinical significance 
to the surgeon. Knowing the chemical composition of the gallstone do not 
alter the surgical management. However, this information will certainly help 
treat these patients without surgery. Drugs like Ursodiol, a biliary acid that is 
used to prevent and treat gallstones, may be better indicated if the chemical 
composition of the gallstone is known.
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